Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
VeroScience
VeroScience
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Cycloset
Bromocriptine
2009-05-05
2023-2032
Parkinson disease
,
Amenorrhea
,
Infertility
,
Adenoma
,
Hypogonadism
,
Hyperprolactinemia
,
Acromegaly
,
Neuroleptic malignant syndrome
,
Galactorrhea
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Bromocriptine
anorexia
,
anorexia nervosa
,
adenomyosis
,
ovarian hyperstimulation syndrome
,
syndrome
,
brain injuries
,
obesity
,
type 1 diabetes mellitus
,
consciousness disorders
,
hemorrhage
,
traumatic brain injuries
,
cerebral hemorrhage
,
subarachnoid hemorrhage
,
subdural hematoma
,
fever
,
hematoma
,
intellectual disability
,
stereotyped behavior
,
macular edema
,
alzheimer disease
,
pituitary diseases
,
heart failure
,
cardiovascular diseases
,
chronic pain
,
myofascial pain syndromes
,
fibromyalgia
,
hypersensitivity
,
liver cirrhosis
,
fibrosis
,
parkinsonian disorders
,
adenoma
,
growth disorders
,
graves ophthalmopathy
,
eye diseases
,
perceptual disorders
Bromocriptine mesylate
healthy volunteers/patients
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use